GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Revenue

Cibus (CBUS) Revenue : $2.32 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cibus Revenue?

Cibus's revenue for the three months ended in Mar. 2024 was $0.55 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $2.32 Mil. Cibus's Revenue per Share for the three months ended in Mar. 2024 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.14.

Warning Sign:

Cibus Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Cibus was -19.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -82.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -37.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 9 years, Cibus's highest 3-Year average Revenue per Share Growth Rate was 348.50% per year. The lowest was -82.90% per year. And the median was 50.05% per year.


Cibus Revenue Historical Data

The historical data trend for Cibus's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus Revenue Chart

Cibus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only 7.30 23.85 25.99 0.16 1.82

Cibus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.20 0.48 1.10 0.55

Competitive Comparison of Cibus's Revenue

For the Biotechnology subindustry, Cibus's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cibus's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's Revenue distribution charts can be found below:

* The bar in red indicates where Cibus's Revenue falls into.



Cibus Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cibus  (NAS:CBUS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Cibus Revenue Related Terms

Thank you for viewing the detailed overview of Cibus's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cibus (CBUS) Business Description

Traded in Other Exchanges
N/A
Address
6455 Nancy Ridge Drive, San Diego, CA, USA, 92121
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.
Executives
Rory B Riggs director, officer: Chief Executive Officer 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr. director 1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn 10 percent owner C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante director SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn director VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann director 21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker director 13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King officer: Chief Financial Officer 750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William officer: See Remarks 13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham director, officer: See Remarks 6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill director C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr director, officer: President and CEO 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak officer: Chief Financial Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter officer: Chief Business Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas officer: Chief Science Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113